Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CAPILLARYS 3 DBS devices.

On August 24, NHC issued the Birth Defects Prevention and Control Plan (2023-2027), proposing that by 2027, China's birth defects prevention and control services will be more universally accessible, and that the prenatal genetic screening rate to reach 90%.

New research will help health-care practitioners to more accurately diagnose disease and illness in newborn babies from urine samples, according to a study by researchers at the University of Alberta and the Universidad Autónoma de Zacateca